These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33660420)

  • 21. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
    Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
    Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
    Clemens KE; Quednau I; Klaschik E
    Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
    Leppert W
    Adv Ther; 2010 Oct; 27(10):714-30. PubMed ID: 20799006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction.
    Leppert W
    Curr Drug Targets; 2014 Jan; 15(1):124-35. PubMed ID: 24020972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy.
    Comelon M; Wisloeff-Aase K; Raeder J; Draegni T; Undersrud H; Qvigstad E; Bjerkelund CE; Lenz H
    Acta Anaesthesiol Scand; 2013 Apr; 57(4):509-17. PubMed ID: 23301686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain.
    Patel J; Lucas CJ; Margalit M; Martin JH
    J Pain Palliat Care Pharmacother; 2018; 32(2-3):116-123. PubMed ID: 30735070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.
    Blagden M; Hafer J; Duerr H; Hopp M; Bosse B
    Neurogastroenterol Motil; 2014 Dec; 26(12):1792-801. PubMed ID: 25346155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.
    Dunlop W; Uhl R; Khan I; Taylor A; Barton G
    J Med Econ; 2012; 15(3):564-75. PubMed ID: 22313329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of prolonged-release oxycodone/naloxone on pain control, bowel function and quality of life: A prospective observational study.
    Hesselbarth S; Löwenstein O; Cegla T
    Scand J Pain; 2014 Apr; 5(2):75-81. PubMed ID: 29913668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.
    Ahmedzai SH; Leppert W; Janecki M; Pakosz A; Lomax M; Duerr H; Hopp M
    Support Care Cancer; 2015 Mar; 23(3):823-30. PubMed ID: 25218610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
    Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
    Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacovigilance in Hospice/Palliative Care: De-Prescribing Combination Controlled Release Oxycodone-Naloxone.
    Clark K; Byrne PG; Hunt J; Brown L; Rowett D; Watts G; Lovell M; Currow DC
    J Palliat Med; 2020 May; 23(5):656-661. PubMed ID: 31904310
    [No Abstract]   [Full Text] [Related]  

  • 34. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
    Morlion B; Clemens KE; Dunlop W
    Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
    Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
    Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged-release oxycodone/naloxone in opioid-naïve patients - subgroup analysis of a prospective observational study.
    Hesselbarth S; Hermanns K; Oepen P
    Expert Opin Pharmacother; 2015 Mar; 16(4):457-64. PubMed ID: 25612469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
    Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
    Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
    Hermanns K; Junker U; Nolte T
    Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
    Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
    Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.